Publications by authors named "B K Arun"
Triple negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the heterogeneity characteristic of TNBC. To that end, we established a biobank of 92 orthotopic patient-derived xenograft (PDX) models of TNBC from the tumors of 75 patients enrolled in the ARTEMIS clinical trial ( NCT02276443 ) at MD Anderson Cancer Center, including 12 longitudinal sets generated from serial patient biopsies collected throughout NACT and from metastatic disease.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of the anti-EGFR monoclonal antibody panitumumab combined with carboplatin and paclitaxel for treating chemotherapy-resistant triple-negative breast cancer (TNBC) patients.
- It included 43 patients who had not sufficiently responded to prior doxorubicin and cyclophosphamide treatment, achieving a combined pathological complete response/residual cancer burden class I rate of 30.2%.
- The results indicate that panitumumab shows promise as part of neoadjuvant therapy for TNBC, warranting further evaluation in larger clinical trials.
Background: Women with high-risk breast lesions, such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), have a 4- to tenfold increased risk of breast cancer compared to women with non-proliferative breast disease. Despite high-quality data supporting chemoprevention, uptake remains low. Interventions are needed to break down barriers.
View Article and Find Full Text PDFArticle Synopsis
- Mutations in the BRCA1 and BRCA2 genes significantly increase breast cancer risk and are present in about 5% of unselected breast cancer patients.
- Breast cancer associated with these mutations has unique characteristics and responds better to specific treatments like PARP inhibitors and platinum-based therapies, while showing less sensitivity to CDK4/6 inhibitors.
- Challenges in identifying patients with these mutations due to low genetic testing rates are discussed, along with current guidelines for testing and the need for timely determination of mutation status to optimize treatment strategies.